H5N1 With or Without Topical Aldara in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

March 4, 2019

Study Completion Date

March 4, 2019

Conditions
Avian InfluenzaInfluenza Immunisation
Interventions
OTHER

Aqueous Cream B.P.

Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.

DRUG

Imiquimod

Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.

BIOLOGICAL

Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04

Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04

Trial Locations (1)

77030-3411

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03472976 - H5N1 With or Without Topical Aldara in Healthy Adults | Biotech Hunter | Biotech Hunter